BLOG

BLOG

2024-07-09

News Update Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors

MORRISVILLE, N.C., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for JCXH-211 intravenous (IV), a novel, first-in-class self-replicating mRNA (srRNA) encoding the engineered human interleukin (IL)-12 protein.
More +

2024-06-06

News Update Immorna Biotherapeutics Presents Clinical Data for JCXH-211, a Self-Replicating RNA Encoding the Human IL-12, at ASCO 2024

Immorna Biotherapeutics Presents Clinical Data for JCXH-211, a Self-Replicating RNA Encoding the Human IL-12, at ASCO 2024
More +

2023-05-31

News Update Immorna Announces First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles

MORRISVILLE, N.C., May 30, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the first subject has been dosed in the Company's First-In-Human (FIH) Phase 1 multi-center study of JCXH-105, a self-replicating RNA (srRNA) vaccine being developed for the prevention of Shingles (Herpes Zoster; HZ). JCXH-105 represents Immorna's first investigational vaccine targeting infection caused by a latent virus.
More +

2023-01-09

News Update Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine

MORRISVILLE, N.C., January 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a Phase 1 multi-center study of JCXH-105, a self-replicating RNA (srRNA) vaccine against Shingles (Herpes Zoster). JCXH-105 represents Immorna’s first investigational vaccine targeting chronic infection caused by a latent virus.
More +

2022-11-19

News Update Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine

MORRISVILLE, N.C., November 21st, 2022 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a Phase 1/2 multi-center study of JCXH-221, a lipid nanoparticle (LNP) complexed broadly protective mRNA vaccine against SARS-CoV-2 infection and diseases. The goal of this multi-center study is to assess the safety and immunogenicity of JCXH-221 in healthy adult subjects.
More +

2022-11-07

News Update First Patient Dosed in Phase 1 FIH Study of JCXH-211, the First-in-Class Self-Replicating RNA encoding human IL-12, in Patients with Malignant Solid Tumors

Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the first patient has been dosed at The University of Texas MD Anderson Cancer Center in the Phase 1 First-in-Human (FIH) trial of JCXH-211 in patients with malignant solid tumors. JCXH-211 is a novel, first-in-class, lipid nanoparticle (LNP) encapsulated self-replicating RNA (srRNA) encoding human interleukin (IL)-12 protein.
More +
< 123 >

Business license

Statement

SEO